Tamiflu (Oseltamivir Phosphate) is an antiviral medication primarily used for the treatment and prevention of influenza A and influenza B. It works by blocking the actions of neuraminidase, an enzyme produced by the influenza virus that enables the virus particles to be released from infected cells and infect other cells. Tamiflu comes as capsules to take orally and is available in generic form. It is effective against both influenza A and B viruses, including H1N1.

The Tamiflu (Oseltamivir Phosphate) market is estimated to be valued at US$ 464.4 Mn in 2023 and is expected to exhibit a CAGR of 3.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The growth of the Tamiflu (Oseltamivir Phosphate) market is majorly driven by the increasing prevalence of influenza worldwide. As per WHO, influenza infects 5-10% of adults and 20-30% of children globally every year. Influenza infection may lead to hospitalization and severe complications such as pneumonia in high-risk populations like children, elderly, and pregnant women. Growing awareness about influenza prevention and treatment options among the global population is expected to augment the demand for Tamiflu (Oseltamivir Phosphate) during the forecast period. Moreover, easy availability of generic versions of Tamiflu at lower costs compared to branded formulations is also contributing to the market growth. However, side effects associated with Tamiflu including nausea, vomiting, diarrhea may hinder the market growth.

Explorer more information on this topic, Please visit @ http://insightfulmarket.weebly.com/blog/antiviral-drugs-is-fastest-growing-segment-fueling-the-growth-of-tamiflu-oseltamivir-phosphate-market